Although NCX and TRP channels represent a relatively new field of cancer research with most studies still in their infancy, they hold tremendous potentials that have yet to be uncovered in the hopes of achieving major clinical breakthroughs in GC therapy. This evidence concerns the gene TLX2 and cancer.